One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P®/Humate P® treatment in von Willebrand disease patients by de Jager, N.C.B. (Nico C. B.) et al.
J Thromb Haemost. 2019;00:1–11.	 	 	 | 	1wileyonlinelibrary.com/journal/jth
 
Received:	27	May	2019  |  Accepted:	20	September	2019
DOI: 10.1111/jth.14652  
O R I G I N A L  A R T I C L E
One piece of the puzzle: Population pharmacokinetics of FVIII 
during perioperative Haemate P®/Humate P® treatment in von 
Willebrand disease patients
Nico C. B. de Jager1 |   Laura H. Bukkems1  |   Jessica M. Heijdra2  |    
Carolien H. C. A. M. Hazendonk2 |   Karin Fijnvandraat3 |   Karina Meijer4 |   
Jeroen Eikenboom5  |   Britta A. P. Laros ‐ van Gorkom6 |   Frank W. G. Leebeek7 |   
Marjon H. Cnossen2 |   Ron A. A. Mathôt1 |   for the OPTI‐CLOT group†
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution‐NonCommercial‐NoDerivs	License,	which	permits	use	and	distribution	in	
any	medium,	provided	the	original	work	is	properly	cited,	the	use	is	non‐commercial	and	no	modifications	or	adaptations	are	made.
















































externally	 validated	 and	 reestimated	 with	 independent	 clinical	 data	 from	 20	 ad‐
ditional	patients	undergoing	31	 surgeries	 and	208	plasma	measurements	of	FVIII.	
The	 observed	 PK	 profiles	 were	 best	 described	 using	 a	 one‐compartment	 model.	
Typical	values	for	volume	of	distribution	and	clearance	were	3.28	L/70	kg	and	0.037	
L/h/70	kg.	Increased	VWF	activity,	decreased	physical	status	according	to	American	
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1  | INTRODUC TION
Von	Willebrand	disease	(VWD)	is	the	most	common	inherited	bleeding	








normalities.	Whereas	 type	 1	 VWD	 describes	 a	 partial	 and	 type	 3	
VWD	a	complete	quantitative	VWF	deficiency,	 type	2	VWD	com‐









A	 widely	 used	 plasma‐derived	 VWF	 concentrate	 in	 patients	
with	VWD	is	Haemate	P®	or	Humate	P®.5 This concentrate contains 
both	VWF	and	FVIII	in	a	ratio	of	2.4:1.	Interindividual	variability	in	
achieved	 levels	 after	 infusion	 of	 this	 VWF/FVIII‐containing	 con‐
















patients	using	 this	 specific	VWF/FVIII	 concentrate	 call	 for	 additional	
tools	to	dose	more	adequately.	Population	PK	modeling	and	subsequent	



































•	 A	 population	 pharmacokinetic	 model	 for	 Haemate	 P	
based	on	FVIII	levels	was	developed.
•	 The	FVIII	levels	after	Haemate	P	administration	were	ad‐
equately	 described	 by	 the	 population	 pharmacokinetic	
model.
•	 The	 population	 pharmacokinetic	 model	 could	 facilitate	
more	accurate	perioperative	dosing	for	VWD	patients.
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correlating	with	the	PK	parameters	of	FVIII.	The	population	model	






from	 a	multicenter	 retrospective	 cohort	 study	 performed	 by	 the	
OPTI‐CLOT	study	group,	conducted	in	five	Academic	Haemophilia	
Treatment	 Centers	 in	 the	 Netherlands.6	 This	 first	 data	 set	 is	 re‐












graphics,	 surgical	characteristics,	and	 treatment	 information.	Patient	
demographics	included	sex,	age,	height,	weight,	blood	group,	hemoglo‐
bin	levels,	baseline	VWF:antigen	(VWF:Ag),	VWF	activity	(VWF:Act),	
and	FVIII	activity	 levels	 (lowest	 levels	ever	measured	in	the	patient),	


















data characteristics is documented in Table 1.
2.2 | Population PK modeling
The	 population	 PK	 modeling	 approach	 analyzes	 the	 data	 from	 all	






levels	 after	 administration	 of	 this	 specific	 VWF/FVIII	 concentrate	
in	 the	 perioperative	 setting	was	 developed	 using	 nonlinear	mixed	






































of	 nonsteroidal	 anti‐inflammatory	 drugs,	 tranexamic	 acid	 and/or	




tial	covariates	could	be	 identified	and	subsequently	be	 included	 in	
4  |     de JAGeR eT AL.




Number	of	patients 97 ‐ 20 ‐ 117 ‐
Female	sex 66 (68%) 12 (60%) 78 (67%)
Age	(y) 50 (0.5‐82) 48.5 (6.0‐76.0) 50 (0.5‐82)
Height	(cm)a 173 (69‐194) 170 (120‐183) 172 (69‐194)
Weight	(kg) 76.0 (8.8‐118.0) 83.0 (24.0‐112.0) 77.0 (8.8‐118.0)
Blood	group	Oa 49 (51%) 9 (45%) 58 (50%)
Baseline	FVIII	level	(IUmL‐1) 0.41 (0.01‐0.97) 0.40 (0.1‐0.7) 0.41 (0.01‐0.97)
Baseline	VWF:Act	level	(IUmL‐1) 0.16 (0.0‐0.58) 0.11 (0.05‐0.31) 0.15 (0.0‐0.58)
Baseline	VWF:Ag	level	(IUmL‐1) 0.28 (0.0‐0.93) 0.22 (0.07‐0.56) 0.28 (0.0‐0.93)
Liver	function	disordersa 18 (19%) 1 (5%) 19 (16%)
Surgical	characteristics
Number	of	patients	undergoing
1	surgery 69 (71%) 13 (65%) 82 (70%)
2	surgeries 16 (16%) 5 (25%) 21 (18%)
3	surgeries 10 (10%) 1 (5%) 11 (9%)
4	surgeries 0 (0%) 0 (0%) 0 (0%)
5	surgeries 1 (1%) 1 (5%) 2 (2%)
6	surgeries 1 (1%) 0 (0%) 1 (1%)
Duration	of	procedure	(min) 71 (7‐470) 48 (10‐387) 65 (7‐470)
Number	of	occasions/surgeries 141 ‐ 31 ‐ 172 ‐
Diagnosis	per	occasion
Number	of	VWD‐type	diagnoses
1 66 (47%) 15 (48%) 81 (47%)
2A 34 (24%) 12 (39%) 46 (27%)
2B 8 (6%) 2 (6%) 10 (6%)
2M 17 (12%) 2 (6%) 19 (11%)
2N 8 (6%) 0 (0%) 8 (5%)
3 8 (6%) 0 (0%) 8 (5%)
Number	of	ASA	classificationsa
II 99 (82%) 27 (87%) 126 (83%)
III 21 (17%) 4 (13%) 25 (16%)
IV 1 (1%) 0 (0%) 1 (1%)
Severity	of	surgical	procedure
Minor 37 (26%) 12 (39%) 49 (28%)
Major 104 (74%) 19 (61%) 123 (72%)
Treatment	information
Haemate	P®	dosages	per	occasion 5 (1‐30) 7 (2‐20) 5 (1‐30)
FVIII	dose	(IU/kg) 22.1 (5.5‐66.1) 16.7 (5.6‐50.0) 20.8 (5.5‐66.1)
Tranexamic	acid	use	during	occasion 59 (42%) 9 (29%) 68 (40%)
NSAID	use	during	occasion 6 (4%) 3 (10%) 9 (5%)
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lute	 percentage	 error	 (Equation	 2),	 respectively,	 representing	 bias	
and inaccuracy.
where Cpred	 represents	 the	 population	 predication,	Cipred the indi‐









From	 a	 total	 of	 97	 patients,	 684	 FVIII	 measurements	 were	 col‐
lected	and	used	for	model	building,	while	the	remaining	208	FVIII	
samples	 of	 20	 patients	were	 used	 for	 external	 validation	 of	 the	
developed	 model.	 Factor	 VIII	 levels	 after	 administration	 of	 the	








monitored	 for	 a	period	 ranging	 from	1	 to	22	days	 after	 surgery.	
The	median	number	of	FVIII	measurements	during	hospitalization	
was	 5	 (ranging	 from	 1	 to	 14).	 Younger	 patients	 were	 underrep‐
resented,	 as	 only	 seven	 children	with	 a	median	 age	 of	 14	 years	
(range:	 0.5‐16	 years)	 and	 median	 body	 weight	 of	 54	 kg	 (range:	
8.8‐107	kg)	were	included.	None	of	the	FVIII	samples	was	below	
the	 lower	 limit	 of	 quantification	 (0.01	 IU/mL).	 Hemostatic	 com‐






















duration	 increased	 from	 45	 to	 106	min	 (interquartile	 range),	 CL	
decreased	with	38%.	Additionally,	when	 the	VWF:Act	 increased	
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bias	 and	acceptable	 inaccuracy.	The	goodness‐of‐fit	 plots	of	 the	
validation	(Supplement	1	in	Appendix	S1)	depict	the	same	results	









distributed around the line y = x.	Figure	2A	shows	the	predicted	
FVIII	levels	based	on	the	population	PK	parameters	with	covariate	
adjustment.	 Since	 IIV	 is	 not	 taken	 into	 account,	 large	deviations	
from	 the	 line	y = x	 are	observed.	Figure	2B	displays	 the	 individ‐
ual	 predicted	 FVIII	 levels	 compared	 to	 the	 observed	 levels.	 The	
individual	 predicted	 levels	 are	 calculated	by	using	 the	 individual	
PK	parameters	estimated	by	Bayesian	analysis.	Smaller	deviations	
around the line y = x	 are	 observed	 as	 IIV	 of	 the	 PK	 parameters	








Bootstrap	 confirmed	 the	 robustness	 of	 the	 parameter	 estimates	
obtained	 in	 the	 final	FVIII	PK	model.	Estimated	parameters	of	 the	
intermediate	 and	 final	 validated	 FVIII	 PK	 model	 parameters	 and	
bootstrap	values	can	be	found	in	Table	2.
4  | DISCUSSION
The	 aim	 of	 this	 study	was	 to	 develop	 a	 population	 PK	model	 de‐
scribing	 FVIII	 levels	 after	 administration	 of	 a	 specific	 VWF/FVIII	




A	 one‐compartment	 PK	 model	 was	 able	 to	 fit	 the	 available	
data	describing	FVIII	 levels	 after	 administration	of	 the	VWF/FVIII	
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concentrate	 in	 the	perioperative	setting.	Almost	all	 achieved	FVIII	
levels	 of	 included	 study	 patients	were	well	 above	 predefined	 tar‐
gets	as	stated	by	national	guidelines,	specifically	95.2%	during	the	
first	 36	 h	 and	 98.9%	 in	 the	 subsequent	 period.13	 Twenty‐five	 of	





demonstrated	 feasibility	 in	 selection	 of	 the	 loading	 dose	 prior	 to	







of	 the	 population	 and	 influences	 of	 covariates	 into	 account.26	 A	
covariate	 analysis	 is	 important	 as	 various	 international	 guidelines	
recommend	specific	FVIII	target	 levels	depending	on	the	type	and	
extent	 of	 the	 surgical	 procedure.11,13,27	 Unfortunately,	 correlation	








in	ASA	class	 II.	 This	 can	possibly	be	 linked	 to	earlier	 findings	 that	
patients	with	comorbidities	exhibit	higher	VWF	and	FVIII	 levels.23 
However,	as	FVIII	baseline	levels	are	included	in	this	population	PK	
model,	 a	 decreased	 FVIII	 clearance	 for	 these	 patients	 with	 more	
comorbidities	would	mean	 that	 their	 FVIII	 levels	would	 rise	more	
during	 the	 surgery	 than	 those	 of	 patients	 without	 comorbidities.	
This	has	not	yet	been	observed.	In	the	data	used	for	the	covariate	
analysis	no	patients	were	classified	in	ASA	class	V	(moribund	patient	
not	expected	 to	 survive	24	hrs	with	or	without	an	operation)	 and	
therefore	this	class	could	not	be	included	in	the	final	FVIII	population	
PK	model.28


















Population predicted FVIII:C (IU/mL) Individual predicted FVIII:C (IU/mL)
3 4 5 6
10 2
Population predicted FVIII:C (IU/mL) Time before/after surgery (h)
3 4 5 6 –192 –96 0 96 192 288 384 480
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the	 absence	 of	 sufficient	 data	 to	 describe	 this	 association	 fully.	
The	effect	of	VWF:Ag	on	FVIII	PK	was	also	evaluated;	however,	




FVIII	 PK	model.	Minor	 or	 major	 surgery	 severity	 was	 identified	
as	a	significant	covariate;	however,	the	ASA	classification	system	
and	surgery	duration	achieved	a	higher	statistical	 significance	 in	
the	multivariate	 analysis.	 Von	Willebrand	 disease	 type	was	 also	
expected	 to	 have	 a	 significant	 influence	 on	 the	 PK	 parameters.	
During	 univariate	 analysis,	 this	 covariate	 showed	 a	 significant	
association	with	CL,	 as	 type	2	 and	 type	3,	 respectively,	 showed	
a	 54%	 and	 74%	 higher	 clearance	 relative	 to	 type	 1	 patients.	
However,	this	effect	was	not	significant	when	the	other	covariates	





loading	dose	was	 administrated.	One	possible	 explanation	 could	
be	that	VWD	type	has	less	effect	on	the	FVIII	clearance	than	ex‐













FVIII	 concentrate	 between	 VWD	 patients.	 The	 estimated	 IIV	 of	
CL	 became	 smaller	 when	 interoccasion	 variability	 was	 taken	 into	
account.	 The	 latter	 quantifies	 the	 intrapatient	 variability	 of	 CL.	
Unfortunately,	 inclusion	of	 interoccasion	variability	on	CL	resulted	
in	an	unstable	model	and	 it	was	 therefore	excluded.	The	 large	 IIV	
on	CL	could,	however,	be	partially	explained	by	introduction	of	the	
statistically	 significant	 covariates.	 However,	 after	 reestimation	 of	
the	PK	parameters	 using	both	 subsets,	 IIV	on	CL	 increased	 again.	
This	can	be	explained	by	the	fact	that	the	validation data set	differed	











possible	 yet	 to	 detect	 endogenous	FVIII	 as	 a	 separate	 entity.	 The	
terminal	half‐life	calculations	can	be	misleading,	because	of	subse‐
quent	 increases	 in	 endogenous	 FVIII	 after	 increase	 of	 exogenous	
and	 endogenous	 VWF	 after	 administration	 of	 this	 specific	 VWF/

























































this	could	be	a	 first	step	 into	 the	direction	of	PK‐guided	dosing	 in	
VWD	patients	undergoing	surgery	treated	with	this	specific	VWF/














This	 study	 was	 performed	 by	 the	 international	 multicenter	 OPTI‐























ber	 for	 a	 study	 sponsored	by	Roche.	M.	H.	Cnossen	has	 received	





no	 competing	 financial	 interests.	 All	 unrestricted	 research	 grants,	






sistance	 of	 J.	M.	Heijdra.	 R.A.	A.	Mathôt	 and	M.	H.	Cnossen	 su‐
pervised	 the	 study,	while	F.W.	G.	 Leebeek	gave	 critical	 guidance.	






Laura H. Bukkems  https://orcid.org/0000‐0001‐7967‐1023 
Jessica M. Heijdra  https://orcid.org/0000‐0003‐1069‐8097 
Jeroen Eikenboom  https://orcid.org/0000‐0002‐3268‐5759 
R E FE R E N C E S
	 1.	 Sadler	 JE,	 Mannucci	 PM,	 Berntorp	 E,	 et	 al.	 Impact,	 diagno‐





	 3.	 Leebeek	F,	Eikenboom	J.	Von	Willebrand's	disease.	N Engl J Med. 
2016;375:2067‐2080.
	 4.	 Sadler	JE,	Mannucci	PM,	Mazurier	C,	et	al.	Update	on	the	patho‐
physiology	 and	 classification	 of	 von	Willebrand	 disease:	 a	 report	
of	the	subcommittee	on	von	Willebrand	factor.	J Thromb Haemost. 
2006;4:2103‐2114.
	 5.	 Berntorp	 E.	 Haemate	 P/Humate‐P:	 a	 systematic	 review.	 Thromb 
Res.	2009;124:S11‐S14.
	 6.	 Hazendonk	H,	 Heijdra	 JM,	 de	 Jager	 N,	 et	 al.	 Analysis	 of	 current	
perioperative	 management	 with	 Haemate®	 P/Humate	 P® in von 








Humate	‐P:	history	and	clinical	performance.	Eur J Haematol Suppl. 
2008;70:3‐35.
	10.	 Rodeghiero	F,	Castaman	G,	Meyer	D,	 et	 al.	Replacement	 therapy	
with	virus‐inactivated	plasma	concentrates	 in	von	Willebrand	dis‐
ease. Vox Sang.	1992;62:193‐199.
	11.	 Laffan	 MA,	 Lester	 W,	 O'Donnell	 JS,	 et	 al.	 The	 diagnosis	 and	
management	 of	 von	Willebrand	 disease:	 a	 United	 Kingdom	 hae‐
mophilia	 centre	 doctors	 organization	 guideline	 approved	 by	 the	
British	 committee	 for	 standards	 in	 haematology.	 Br J Haematol. 
2014;167:453‐465.
     |  11de JAGeR eT AL.
	12.	 Ewenstein	BM.	Use	of	 ristocetin	cofactor	activity	 in	 the	manage‐
ment	of	von	Willebrand	disease.	Haemophilia.	2001;7:10‐15.
	13.	 Nederlandse	 Vereniging	 van	 Hemofiliebehandelaars	 (NVHB).	
Richtlijn: diagnostiek en behandeling van hemofilie en aanverwante he-
mostasestoornissen.	Amsterdam,	The	Netherlands:	Alphen	aan	den	
Rijn:	Van	Zuiden	Communications	B.V.;	2009.	




	15.	 Koshy	BM,	Weiner	 SJ,	Miller	 ST,	 et	 al.	 Surgery	 and	 anesthesia	 in	
sickle	cell	disease.	Cooperative	study	of	sickle	cell	diseases.	Blood. 
1995;86:3676‐3684.
	16.	 Kaufmann	 JE,	 Vischer	 UM.	 Cellular	 mechanisms	 of	 the	 hemo‐
static	 effects	 of	 desmopressin	 (DDAVP).	 J Thromb Haemost. 
2003;1:682‐689.
	17.	 Keizer	 RJ,	 van	Benten	M,	 Beijnen	 JH,	 et	 al.	 Piraña	 and	 PCluster:	
a	modeling	environment	and	cluster	infrastructure	for	NONMEM.	
Comput Methods Programs Biomed.	2011;101:72‐79.
	18.	 Lindbom	 L,	 Pihlgren	 P,	 Jonsson	 N.	 PsN‐Toolkit	 ‐	 a	 collection	 of	
computer	 intensive	 statistical	 methods	 for	 non‐linear	 mixed	 ef‐





	20.	 R	Core	Team.	R: A language and environment for statistical computing. 
Vienna,	Austria:	R	Foundation	for	Statistical	Computing.
	21.	 Lee	LJ,	John	K,	Wu	M‐CP,	Shannon	J	An	increase	in	factor	VIII	levels	







lated	 increase	 of	 VWF	 in	 von	Willebrand	 disease.	Br J Haematol. 
2018;182:93‐105.
	24.	 Anderson	 BJ,	 Holford	 N.	 Mechanism‐based	 concepts	 of	 size	
and	 maturity	 in	 pharmacokinetics.	 Annu Rev Pharmacol Toxicol. 
2008;48:303‐332.
	25.	 Jonsson	 EN,	 Karlsson	 MO.	 Automated	 covariate	 model	 building	
within	NONMEM.	Pharm Res.	1998;15:1463‐1468.




	27.	 Nichols	WL,	Hultin	MB,	 James	AH,	et	 al.	 von	Willebrand	disease	
(VWD):	evidence‐based	diagnosis	and	management	guidelines,	the	






factor	 interaction:	biological,	 clinical	 and	 therapeutic	 importance.	
Haemophilia.	2010;16:3‐13.










and	 clinical	 phenotype	 of	 severe	 hemophilia	 A.	 Haematologica. 
2005;90:494‐498.
SUPPORTING INFORMATION
Additional	 supporting	 information	 may	 be	 found	 online	 in	 the	
Supporting	Information	section	at	the	end	of	the	article.	




patients.	J Thromb Haemost. 2019;00:1–11. https	://doi.
org/10.1111/jth.14652	
APPENDIX 
Steering	 Committee,	 the	 Netherlands:	 M.	 H.	 Cnossen	 (principal	
Investigator	 and	 chair	OPTI‐CLOT),	 F.	W.	G.	 Leebeek,	 Rotterdam;	
K.	Fijnvandraat,	R.	A.	A.	Mathôt,	Amsterdam;	K.	Meijer,	Groningen.
Local	principal	investigators,	other	local	collaborators,	and	PhDs,	
the	 Netherlands:	 M.	 J.	 H.	 A.	 Kruip,	 S.	 Polinder,	 J.	 Lock,	 H.	 C.	 A.	
M.	Hazendonk,	 I.	 van	Moort,	 J.	M.	Heijdra,	M.	C.	H.	 J.	Goedhart,	
Rotterdam;	M.	 Coppens,	M.	 Peters,	 T.	 Preijers,	NCB	 de	 Jager,	 LH	
Bukkems,	Amsterdam;	R.	Y.	J.	Tamminga,	Groningen;	B.	A.	P.	Laros‐
van	 Gorkom,	 P.	 Brons,	 Nijmegen;	 F.	 J.	 M.	 van	 der	 Meer,	 H.	 C.	 J.	
Eikenboom,	Leiden;	R.	E.	G.	Schutgens,	K.	Fischer,	Utrecht;	M.	H.	E.	
Driessens,	Nijkerk.	Trial	bureau:	C.	M.	Zwaan,	I.	van	Vliet,	Rotterdam.	
Principal	investigators	and	local	collaborators	in	the	United	Kingdom:	
P.	W.	Collins,	Cardiff;	R.	Liesner,	P.	Chowdary,	London;	D.	Keeling,	
Oxford.	We	thank	all	hemophilia	and	research	nurses	for	their	dedi‐
cation	and	support	for	this	project.
